Redeye updates on Embracer after its Q3-results which were stronger-than-expected while the updated ...
CDON delivered a strong fourth quarter with accelerating momentum across key operational metrics.
Redeye returns with an updated view following Nekkar’s Q4 figures that posted a welcome recovery.
Relais' Q4 was soft, with the top line and adjusted EBITA below LSEG Data & Analytics consensus.
Redeye updates its view following Ferroamp’s strong Q4 report, which showed 95% sales growth and mat...
Redeye retains its positive view of Carasent following the Q4 report.
* We expect 50% organic growth in Q4e * Q4 mix is likely to be somewhat soft * FVR of SEK 30-45 reit...
* Strong US performance more than offsets German weakness * EBIT up by 5-9% for '26e-'27e, driven by...
* Sales up 3% y-o-y, held back by soft volumes and tough comps * We keep sales flat, and slightly ra...
* Offering a business opportunity to system operators * Identifying the potential in closed-loop sys...
Redeye expects Smart Eye’s Q4 report, due 17 February, to show 13% y/y net sales growth and to reach...
Nettoomsättningen i det fjärde kvartalet uppgick till 154,4 MSEK (119,8), motsvarande en tillväxt om...
* Q4 sales -16% vs. ABGSCe, miss in GC&MP and FW * NW&FT showing positive signs; we see a return to ...
Redeye concludes that Litium delivered a strong Q4, with ARR growth of 18% including Geins and organ...
CDON delivered an in-line Q4 report. GMV of SEK 644m was 3% above our estimate of SEK 627m and growi...
* A soft end to '25 on earnings * We cut '26e-'27e adj.
Analytikerna rättar namnet på Precise Biometrics vd som är Joakim Nydemark.
Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report.
Q4 var stabilt: omsättningen ökade 1 % till 3 224 mkr och marginalen stärktes till 5,0 %.
Marimekko's Q4 came in slightly below our estimates, with profitability disappointing, particularly ...
